Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin

INTRODUCTION: Severe, nonresponsive, primary focal segmental glomerular sclerosis (FSGS) can progress to end-stage kidney disease (ESKD) in <5 years. Soluble urokinase-type plasminogen activator receptor (suPAR) may contribute to podocyte effacement by activating podocyte β3 integrin. It has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Hladunewich, Michelle A., Cattran, Dan, Sethi, Sanjeev M., Hayek, Salim S., Li, Jing, Wei, Changli, Mullin, Sarah I., Reich, Heather N., Reiser, Jochen, Fervenza, Fernando C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720804/
https://www.ncbi.nlm.nih.gov/pubmed/35005315
http://dx.doi.org/10.1016/j.ekir.2021.10.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720804/
https://www.ncbi.nlm.nih.gov/pubmed/35005315
http://dx.doi.org/10.1016/j.ekir.2021.10.017

Ejemplares similares